DCPH - Deciphera Pharmaceuticals Inc Stock Price, Fair Value and News

$25.59

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

DCPH Price Action

Last 7 days

0.1%

Last 30 days

0.8%

Last 90 days

50.9%

Trailing 12 Months

82.9%

DCPH RSI Chart

DCPH Valuation

Market Cap

2.2B

Price/Earnings (Trailing)

-11.62

Price/Sales (Trailing)

12.65

EV/EBITDA

-11.02

Price/Free Cashflow

-14.52

DCPH Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

DCPH Fundamentals

DCPH Revenue

Revenue (TTM)

174.9M

Rev. Growth (Yr)

34.55%

Rev. Growth (Qtr)

-6.82%

DCPH Earnings

Earnings (TTM)

-190.4M

Earnings Growth (Yr)

9.12%

Earnings Growth (Qtr)

4.38%

DCPH Profitability

EBT Margin

-111.21%

Return on Equity

-60.24%

Return on Assets

-45.23%

Free Cashflow Yield

-6.89%

DCPH Investor Care

Shares Dilution (1Y)

10.13%

Diluted EPS (TTM)

-2.21

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	174.9M	0	0	0
2023	138.3M	144.1M	151.4M	163.4M
2022	100.2M	109.1M	121.9M	134.0M
2021	67.2M	83.7M	91.4M	96.1M
2020	0	30.7M	36.4M	42.1M
2019	0	0	0	25.0M

Get all data in R, Python etc through our Historical Stock Data APIs

About Deciphera Pharmaceuticals Inc

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

CEO	Mr. Steven L. Hoerter
WEBSITE	deciphera.com
SECTOR	Healthcare
INDUSTRY	Drug Manufacturers Specialty & Generic
EMPLOYEES	300

Deciphera Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Deciphera Pharmaceuticals Inc? What does DCPH stand for in stocks?

DCPH is the stock ticker symbol of Deciphera Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Deciphera Pharmaceuticals Inc (DCPH)?

As of Tue Jun 11 2024, market cap of Deciphera Pharmaceuticals Inc is 2.21 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DCPH stock?

You can check DCPH's fair value in chart for subscribers.

Is Deciphera Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether DCPH is over valued or under valued. Whether Deciphera Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Deciphera Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DCPH.

What is Deciphera Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Jun 11 2024, DCPH's PE ratio (Price to Earnings) is -11.62 and Price to Sales (PS) ratio is 12.65. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DCPH PE ratio will change depending on the future growth rate expectations of investors.